Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orient Europharma CoROCO:4120 -3.38%61 PS Ratio is 0.85 as of Sep. 04, 2026, which is 1% above its 10-year median of 0.84. GuruFocus rates ROCO:4120 with a GF Score™ of 61/100 and a GF Value™ of NT$47.36 (Fairly Valued). The stock has 5 warning signs investors should review. Among 952 Drug Manufacturers companies, Orient Europharma Co ranks better than 78.05% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Orient Europharma Co's share price is NT$45.70.
Orient Europharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$53.77. Hence, Orient Europharma Co's PS Ratio for today is 0.85.
Good Sign:
Orient Europharma Co Ltd stock PS Ratio (=0.88) is close to 2-year low of 0.82.
The historical rank and industry rank for Orient Europharma Co's PS Ratio or its related term are showing as below:
ROCO:4120'
s PS Ratio Range Over the Past 10 Years
Min: 0.55 Med: 0.84 Max: 1.4
Current: 0.85
During the past 13 years, Orient Europharma Co's highest PS Ratio was 1.40. The lowest was 0.55. And the median was 0.84.
ROCO:4120's PS Ratio is ranked better than 78.05% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.345
vs ROCO:4120: 0.85
Orient Europharma Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Orient Europharma Co was 4.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -1.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -2.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -1.70% per year.
During the past 13 years, Orient Europharma Co's highest 3-Year average Revenue per Share Growth Rate was 6.80% per year. The lowest was -8.00% per year. And the median was 2.20% per year.
Orient Europharma Co (ROCO:4120) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Orient Europharma Co PS Ratio Related Terms
Orient Europharma Co PS Ratio Historical Data
* Premium members only.
The historical data trend for Orient Europharma Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Europharma Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Europharma Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Europharma Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Orient Europharma Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Orient Europharma Co's Share Price of today is NT$45.70. Orient Europharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$53.77.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Orient Europharma Co (ROCO:4120) has a PS Ratio of 0.85 as of Sep. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Orient Europharma Co and its competitors. This is near median its historical median of 0.84. Over the past decade, Orient Europharma Co's PS Ratio has ranged from 0.55 to 1.40. According to the industry distribution chart, Orient Europharma Co ranks #209 out of 952 companies in the Drug Manufacturers industry, placing it in the top 22%.
Is Orient Europharma Co's PS Ratio too high?
Orient Europharma Co's current PS Ratio of 0.85 is near median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 1.40. The Drug Manufacturers industry median PS Ratio is 2.35. Orient Europharma Co's value of 0.85 is 63.8% below this industry median. Based on the distribution chart, Orient Europharma Co ranks #209 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orient Europharma Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orient Europharma Co's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orient Europharma Co ranks #209 out of 952 companies for PS Ratio. This places Orient Europharma Co in the top 22% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.35. Orient Europharma Co's value of 0.85 is 63.8% below this benchmark. Historically, Orient Europharma Co's own PS Ratio has ranged from 0.55 to 1.40 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 2.35, Orient Europharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Europharma Co's current PS Ratio of 0.85 is 63.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Orient Europharma Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Europharma Co's current PS Ratio is 0.85, which is near median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Europharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Europharma Co (ROCO:4120) is currently considered Fairly Valued. The stock's GF Value™ is NT$47.36, compared to a current price of NT$45.70 — trading 3.5% below its estimated fair value. The current PS Ratio is 0.85, which is near median its 10-year median of 0.84 and 63.8% below the Drug Manufacturers industry median of 2.35. Orient Europharma Co's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Orient Europharma Co (ROCO:4120), the current PS Ratio is 0.85 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Europharma Co (ROCO:4120) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Europharma Co stock appears to be undervalued.
The current stock price of NT$45.70 is trading 3.5% below its estimated GF Value™ of NT$47.36.
GuruFocus considers Orient Europharma Co to be Fairly Valued.
Key valuation signals for ROCO:4120:
PS Ratio: 0.85 (near median its 10-year median of 0.84)
GF Value™: NT$47.36 vs. price of NT$45.70 (3.5% below fair value)
Industry Position: 63.8% below the Drug Manufacturers median (#209 of 952)
No single metric tells the full story. See the ROCO:4120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
61GF Score
Get the complete analysis for ROCO:4120
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4120 has been successfully added to your 
